Transforming growth factor-β2 is a molecular determinant for site-specific melanoma metastasis in the brain

Cancer Research

Volumn 69, Issue 3, 2009, Pages 828-835

  Zhang, Chenyu ^a   Zhang, Fahao ^a   Tsan, Rachel ^a   Fidler, Isaiah J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METASTASIS; BRAIN VENTRICLE; CARCINOGENICITY; CELL GROWTH; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; LEPTOMENINX; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BRAIN NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA2;

EID: 59149102419     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2588     Document Type: Article

References (37)

1. Patchell RA. The management of brain metastases. Cancer Treat Rev 2003;29:533-40.
2. Johnson JD, Young B. Demographics of brain metastasis. Neurosurg Clin N Am 1996;7:337-44.
3. Sampson JH, Carter JH, Jr., Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998;88:11-20.
4. Schackert G, Fidler IJ. Development of in vivo models for studies of brain metastasis. Int J Cancer 1988;41:589-94.
5. Schackert G, Fidler IJ. Site-specific metastasis of mouse melanomas and a fibrosarcoma in the brain or meninges of syngeneic animals. Cancer Res 1988;48:3478-84.
6. Fujimaki T, Fan D, Staroselsky A, Gohji K, Bucana C, Fidler I. Critical factors regulating site-specific brain metastasis of murine melanomas. Int J Oncol 1993;3:789-99.
7. Sporn MB. The early history of TGF-β, and a brief glimpse of its future. Cytokine Growth Factor Rev 2006;17:3-7.
8. Massague J. TGF-β in cancer. Cell 2008;134:215-30.
9. Bierie B, Moses HL. Tumour microenvironment: TGF-β: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006;6:506-20.
10. de Martin R, Haendler B, Hofer-Warbinek R, et al. Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-β gene family. EMBO J 1987;6:3673-7.
11. Wrann M, Bodmer S, de Martin R, et al. T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-β. EMBO J 1987;6:1633-6.
12. Maxwell M, Galanopoulos T, Neville-Golden J, Antoniades HN. Effect of the expression of transforming growth factor-β2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J Neurosurg 1992;76:799-804.
13. Bodmer S, Strommer K, Frei K, et al. Immunosuppression and transforming growth factor-β in glioblastoma: preferential production of transforming growth factor-β2. J Immunol 1989;143:3222-9.
14. Jachimczak P, Bogdahn U, Schneider J, et al. The effect of transforming growth factor-β2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J Neurosurg 1993;78:944-51.
15. Liau LM, Fakhrai H, Black KL. Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-β antisense gene. Neurol Res 1998;20:742-7.
16. Fakhrai H, Dorigo O, Shawler DL, et al. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc Natl Acad Sci U S A 1996;93:2909-14.
17. Liu Y, Wang Q, Kleinschmidt-DeMasters BK, Franzusoff A, Ng KY, Lillehei KO. TGF-β2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors. J Neurooncol 2007;81:149-62.
18. Hart IR. The selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol 1979;97:587-600.
19. Poste G, Doll J, Hart IR, Fidler IJ. In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties. Cancer Res 1980;40:1636-44.
20. Fidler IJ. Selection of successive tumour lines for metastasis. Nat New Biol 1973;242:148-9.
21. Kripke ML. Speculations on the role of ultraviolet radiation in the development of malignant melanoma. J Natl Cancer Inst 1979;63:541-8.
22. Fidler IJ, Gruys E, Cifone MA, Barnes Z, Bucana C. Demonstration of multiple phenotypic diversity in a murine melanoma of recent origin. J Natl Cancer Inst 1981;67:947-56.
23. Talmadge JE, Fidler IJ. Enhanced metastatic potential of tumor cells harvested from spontaneous metastases of heterogeneous murine tumors. J Natl Cancer Inst 1982;69:975-80.
24. Radinsky R, Beltran PJ, Tsan R, Zhang R, Cone RD, Fidler IJ. Transcriptional induction of the melanocyte-stimulating hormone receptor in brain metastases of murine K-1735 melanoma. Cancer Res 1995;55:141-8.
25. de la Monte SM, Moore GW, Hutchins GM. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res 1983;43:3427-33.
26. Raizer JJ, Hwu WJ, Panageas KS, et al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neurooncol 2008;10:199-207.
27. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003;3:453-8.
28. Fontana A, Hengartner H, de Tribolet N, Weber E. Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol 1984;132:1837-44.
29. Schwyzer M, Fontana A. Partial purification and biochemical characterization of a T cell suppressor factor produced by human glioblastoma cells. J Immunol 1985;134:1003-9.
30. Leitlein J, Aulwurm S, Waltereit R, et al. Processing of immunosuppressive pro-TGF-β1,2 by human glioblastoma cells involves cytoplasmic and secreted furin-like proteases. J Immunol 2001;166:7238-43.
31. + regulatory T cells in the development of tolerance induced by transforming growth factor-β2-treated antigen-presenting cells. Immunology 2008;124:304-14.
32. Ishihara H, Kubota H, Lindberg RL, et al. Endothelial cell barrier impairment induced by glioblastomas and transforming growth factor β2 involves matrix metalloproteinases and tight junction proteins. J Neuropathol Exp Neurol 2008;67:435-48.
33. Fakhrai H, Mantil JC, Liu L, et al. Phase I clinical trial of a TGF-β antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther 2006;13:1052-60.
34. Schlingensiepen R, Goldbrunner M, Szyrach MN, et al. Intracerebral and intrathecal infusion of the TGF-β2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety. Oligonucleotides 2005;15:94-104.
35. Schlingensiepen KH, Schlingensiepen R, Steinbrecher A, et al. Targeted tumor therapy with the TGF-β2 antisense compound AP 12009. Cytokine Growth Factor Rev 2006;17:129-39.
36. Hau P, Jachimczak P, Schlingensiepen R, et al. Inhibition of TGF-β2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 2007;17:201-12.
37. Schlingensiepen KH, Fischer-Blass B, Schmaus S, Ludwig S. Antisense therapeutics for tumor treatment: the TGF-β2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res 2008;177:137-50.